Glucagon-like peptide-1 (GLP-1) receptor agonists have evolved from glucose-lowering agents for type 2 diabetes into transformative therapies reshaping cardiometabolic medicine. In this comprehensive review, Daniel Drucker outlines how GLP-1–based therapies now extend well beyond glycemic control, influencing obesity, cardiovascular disease, peripheral artery disease, obstructive sleep apnea, and potentially multiple non-metabolic disorders.
Glucagon-like peptide-1 (GLP-1) receptor agonists have evolved from glucose-lowering agents for type 2 diabetes into transformative therapies reshaping cardiometabolic medicine. In this comprehensive review, Daniel Drucker outlines how GLP-1–based therapies now extend well beyond glycemic control, influencing obesity, cardiovascular disease, peripheral artery disease, obstructive sleep apnea, and potentially multiple non-metabolic disorders.
These agents exert benefits through several complementary mechanisms: sustained weight reduction, improved insulin sensitivity, attenuation of systemic inflammation, and direct receptor-mediated effects in diverse tissues. The development of long-acting formulations with optimised pharmacokinetics has amplified weight loss and cardiometabolic benefits. Furthermore, next-generation multi-agonist molecules incorporating additional peptide epitopes (e.g., dual or triple incretin-based constructs) are demonstrating enhanced metabolic efficacy.
Importantly, research is expanding into novel indications, including metabolic liver disease, neurodegenerative disorders, substance use disorders, inflammatory bowel disease, arthritis, and even type 1 diabetes. These developments reflect a paradigm shift—from symptom control to disease modification.
However, critical questions remain regarding long-term safety, durability of benefit, comparative effectiveness among agents, access inequities, and economic sustainability.
In summary, GLP-1 medicines are no longer simply antidiabetic drugs; they represent a rapidly expanding therapeutic platform with multisystem implications. The next decade will determine whether these agents achieve their full potential as cornerstone therapies in metabolic and inflammatory disease management.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.